|
Market Closed -
Euronext Bruxelles
09:25:00 05/10/2026 pm IST
|
5-day change | 1st Jan Change | ||
| 200.90 EUR | -1.66% |
|
-5.46% | -15.80% |
| 30/09 | Merck's experimental skin disease drug succeeds in mid-stage study | RE |
| 29/09 | UCB Presents Data From Innovative Myasthenia Gravis Portfolio At AANEM Annual Meeting And MGFA Scientific Session | CI |
| Market Cap | 3.83TCr 4.29TCr 3.57TCr 3.25TCr 6.12TCr 4,13500Cr 6.16TCr 43TCr 17TCr 2,11100Cr 16TCr 16TCr 6,78400Cr | P/E 2026 * |
20.1x | P/E 2027 * | 16.7x |
|---|---|---|---|---|---|
| Enterprise Value | 3.87TCr 4.34TCr 3.61TCr 3.28TCr 6.18TCr 4,18000Cr 6.23TCr 44TCr 17TCr 2,13300Cr 16TCr 16TCr 6,85700Cr | EV / Sales 2026 * |
4.47x | EV / Sales 2027 * | 3.81x |
| Free-Float |
61.59% | Yield 2026 * |
0.72% | Yield 2027 * | 0.75% |
| Markets | Quality | ||
|---|---|---|---|
Euronext Bruxelles
| UCB | Real-time | |
CBOE
| UCB | Real-time | |
|
CBOE
| 0NZT | Real-time | |
|
Tradegate
| UNC | Real-time | |
|
Xetra
| UNC | Delayed | |
|
Börse Stuttgart
| UNC | Delayed | |
|
OTC Markets
| UCBJF | Delayed | |
|
Boerse Muenchen
| UNC | Real-time | |
|
Deutsche Boerse AG
| UNC | Delayed | |
|
London S.E.
| 0NZT | Delayed | |
|
Wiener Boerse
| UCB | End-of-day quote | |
|
Borsa Italiana
| 4UCB | End-of-day quote |
Last Transcript: UCB
| 1 day | -1.66% | ||
| 1 week | -5.46% | ||
| Current month | -2.05% | ||
| 1 month | -4.61% | ||
| 3 months | -22.58% | ||
| 6 months | -24.05% | ||
| Current year | -15.80% |
| 1 week | 200.2 |  | 208.65 |
| 1 month | 200.2 | | 217.1 |
| Current year | 200.2 | | 289.5 |
| 1 year | 200.2 | | 289.5 |
| 3 years | 65.4 | | 289.5 |
| 5 years | 65.4 | | 289.5 |
| 10 years | 54.84 | | 289.5 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 67 | 01/01/2015 | |
Sandrine Dufour
DFI | Director of Finance/CFO | 60 | 01/07/2020 |
Alistair Henry
CTO | Chief Tech/Sci/R&D Officer | 59 | 01/05/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 55 | 01/01/2012 | |
| Director/Board Member | 67 | 01/01/2015 | |
| Director/Board Member | 56 | 24/04/2014 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 15/01/26 | Exercice | Executive/Senior Manager | 3,000 | 0.0015% | ||
| 15/01/26 | Exercice | Executive/Senior Manager | 3,000 | 0.0015% | ||
| 15/01/26 | Buy | Director | 500 | 0.0003% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.66% | -5.46% | -20.28% | +158.69% | 4.38TCr | |
| +0.02% | -3.52% | +36.11% | +111.11% | 1,01900Cr | |
| -1.21% | -6.99% | +34.08% | +60.96% | 62TCr | |
| +1.12% | -0.20% | +13.62% | +80.24% | 46TCr | |
| -3.30% | -6.15% | +56.45% | +34.69% | 36TCr | |
| +0.93% | -1.83% | +21.65% | +41.43% | 33TCr | |
| +0.12% | -4.05% | +10.70% | +33.53% | 27TCr | |
| -0.89% | -5.83% | -7.00% | +7.91% | 24TCr | |
| -0.01% | -3.62% | +35.28% | +52.02% | 22TCr | |
| -0.08% | -4.98% | +28.34% | +93.61% | 18TCr | |
| Average | +0.03% | -3.92% | +20.90% | +67.42% | 37.41TCr | |
| Weighted average by Cap. | +0.42% | -3.65% | +27.93% | +69.55% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 865.9Cr 970.63Cr 806.71Cr 734.14Cr 1.38TCr 93TCr 1.39TCr 9.75TCr 3.79TCr 48TCr 3.64TCr 3.57TCr 1,53400Cr | 960.66Cr 1.08TCr 894.99Cr 814.47Cr 1.53TCr 1,03700Cr 1.55TCr 11TCr 4.21TCr 53TCr 4.04TCr 3.96TCr 1,70100Cr |
| Net income | 192.8Cr 216.12Cr 179.62Cr 163.46Cr 307.82Cr 21TCr 310.1Cr 2.17TCr 844.41Cr 11TCr 811.3Cr 793.79Cr 34TCr | 229.68Cr 257.46Cr 213.98Cr 194.73Cr 366.72Cr 25TCr 369.43Cr 2.59TCr 1.01TCr 13TCr 966.52Cr 945.66Cr 41TCr |
| Net Debt | 41Cr 46Cr 38Cr 35Cr 66Cr 4.45TCr 66Cr 464.55Cr 180.74Cr 2.27TCr 173.65Cr 169.91Cr 7.31TCr | -169.5Cr -190.01Cr -157.92Cr -143.71Cr -270.63Cr -18TCr -272.64Cr -1.91TCr -742.39Cr -9.34TCr -713.28Cr -697.89Cr -30TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 05/26/05 | €200.90 | -1.66% | 1,59,633 |
| 02/26/02 | €204.30 | +1.49% | 1,76,155 |
| 01/26/01 | €201.30 | -1.85% | 2,37,472 |
| 30/26/30 | €205.10 | -0.82% | 3,02,223 |
| 29/26/29 | €206.80 | -2.68% | 3,58,447 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- UCB Stock
Select your edition
All financial news and data tailored to specific country editions
